Top Qs
Timeline
Chat
Perspective

Chikungunya vaccine

Medication From Wikipedia, the free encyclopedia

Remove ads

Chikungunya vaccines are vaccines intended to provide acquired immunity against the chikungunya virus.[7][9]

Quick facts Vaccine description, Target ...

The most commonly reported side effects include headache, fatigue, muscle pain, joint pain, fever, nausea and tenderness at the injection site.[14]

The first chikungunya vaccine was approved for medical use in the United States in November 2023.[14] Chikungunya vaccines were also authorized in the European Union in May 2024.[10][12][15]

In May 2025, the US Food and Drug Administration (FDA) and Centers for Disease Control and Prevention recommended a pause in the use of the chikungunya vaccine (Ixchiq) in people aged 60 years of age and older based on reports of serious neurologic, cardiac, and other adverse events in vaccine recipients.[16] The FDA removed the pause in August 2025.[16] The European Medicines Agency paused the use of the vaccine in people aged 65 years of age and older in May 2025,[17] and resumed its use in July 2025.[18] The UK Medicines and Healthcare products Regulatory Agency paused the use of the vaccine in people aged 65 years of age and older in June 2025.[5][19]

Remove ads

Medical uses

The chikungunya vaccine is indicated for the prevention of disease caused by chikungunya virus.[6][8]

History

The safety of the chikungunya vaccine was evaluated in two clinical studies conducted in North America in which about 3,500 participants 18 years of age and older received a dose of the vaccine with one study including about 1,000 participants who received a placebo.[14] The effectiveness of the chikungunya vaccine is based on immune response data from a clinical study conducted in the United States in individuals 18 years of age and older.[14] In this study, the immune response of 266 participants who received the vaccine was compared to the immune response of 96 participants who received placebo.[14] The level of antibody evaluated in study participants was based on a level shown to be protective in non-human primates that had received blood from people who had been vaccinated.[14] Almost all vaccine study participants achieved this antibody level.[14]

The US Food and Drug Administration (FDA) granted the application for the chikungunya vaccine fast track, breakthrough therapy, and priority review designations.[14] The FDA granted approval of Ixchiq to Valneva Austria GmbH.[14][20]

Remove ads

Society and culture

In May 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agencyadopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Ixchiq, intended for the prevention of chikungunya disease in adults.[10] The applicant for this medicinal product is Valneva Austria GmbH.[10][21] Ixchiq was reviewed under EMA's accelerated assessment program.[10][15] It contains the live attenuated chikungunya virus (CHIKV) Δ5nsP3 strain of the ECSA/IOL genotype.[10] Ixchiq was authorized for medical use in the European Union in June 2024.[10][11]

In January 2025, the CHMP adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vimkunya (chikungunya vaccine (recombinant, adsorbed)), a vaccine intended for the prevention of chikungunya disease in individuals aged twelve years of age and older.[12] The applicant for this medicinal product is Bavarian Nordic A/S.[12][22] Vimkunya was authorized for medical use in the European Union in February 2025.[12][13]

References

Loading related searches...

Wikiwand - on

Seamless Wikipedia browsing. On steroids.

Remove ads